Steglatro is a medicine used to treat adults with type 2 diabetes together with diet and exercise. Steglatro can be used in combination with other diabetes medicines or on its own in patients who cannot take metformin. Steglatro contains the active substance ertugliflozin.
Therapeutic Indication
### Therapeutic indication Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: - as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. - in addition to other medicinal products for the treatment of diabetes.
Therapeutic Area (MeSH)
N/AATC Code
A10BK04
ATC Item
ertugliflozin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| ertugliflozin l-pyroglutamic acid | N/A | Ertugliflozin pidolate |
EMA Name
Steglatro
Medicine Name
Steglatro
Aliases
N/ANo risk management plan link.
